A Study of LAD191 in Adults With Hidradenitis Suppurativa
← catalyst calendarNCT07151937 · readout in 279 d
Sponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
200estimated
Sites
1
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-05 | actual | When the study began enrolling |
| Primary completion | 2027-05-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: LAD191
- Other: Placebo
- Drug: Adalimumab
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Achieving 50 Percent (%) Reduction from Baseline in Hidradenitis Suppurativa Clinical Response (HiSCR-50)
measured At Week 16
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed